Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Exclusion Criteria

• •Use of any of the following treatments or anticipated use of any of the following treatments to the study eye:
• •Intravitreal or periocular corticosteroid, within 90 days prior to Visit 1 (Day 1) and throughout the study.
• •Glaucoma, evidenced by an IOP of \> 21 mmHg despite up to 4 glaucoma medications, or evidence of glaucomatous visual field loss or has advanced glaucoma (e.g., prior shunt surgery) in either eye
• •Evidence of any other ocular disease other than nAMD in the study eye that may confound the outcome of the study (eg, active diabetic retinopathy, posterior uveitis, pseudovitelliform macular degeneration, moderate/severe myopia).
• •Participants with advanced nAMD and no prognosis of BCVA as per Investigator's judgement (e.g. due to macular OCT signs of atrophy or photoreceptors disruption, or macular/foveal subretinal hemorrhage).
• •Need for ocular surgery in the study eye during the course of the study.
• •YAG laser capsulotomy within 30 days prior to Visit 1 in the study eye.
• •Intraocular surgery, including lens removal or laser, within 90 days prior to Visit 1 in the study eye.
• •Ocular or periocular infection in either eye.
• •Pupillary dilation inadequate for quality stereoscopic fundus photography in the study eye.
• •Media opacity that would limit clinical visualization, intravenous fluorescein angiography, or spectral-domain optical coherence tomography (SD-OCT) evaluation in the study eye.
• •History of herpetic infection in the study eye or adnexa.
• •Presence of known active toxoplasmosis, inactive toxoplasmosis or toxoplasmosis scar in either eye.
• •Presence of any form of ocular malignancy including choroidal melanoma in either eye